Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does HEPARIN Cause Malignant neoplasm progression? 25 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Malignant neoplasm progression have been filed in association with HEPARIN (Heparin Sodium). This represents 0.1% of all adverse event reports for HEPARIN.

25
Reports of Malignant neoplasm progression with HEPARIN
0.1%
of all HEPARIN reports
11
Deaths
17
Hospitalizations

How Dangerous Is Malignant neoplasm progression From HEPARIN?

Of the 25 reports, 11 (44.0%) resulted in death, 17 (68.0%) required hospitalization, and 5 (20.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for HEPARIN. However, 25 reports have been filed with the FAERS database.

What Other Side Effects Does HEPARIN Cause?

Drug ineffective (2,294) Heparin-induced thrombocytopenia (2,057) Off label use (1,077) Thrombocytopenia (781) Haemorrhage (684) Pulmonary embolism (652) Drug hypersensitivity (629) Thrombosis (603) Foetal exposure during pregnancy (582) Anaemia (576)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which HEPARIN Alternatives Have Lower Malignant neoplasm progression Risk?

HEPARIN vs HEPARIN\SODIUM HEPARIN vs HEPATITIS B VIRUS VACCINE HEPARIN vs HERBALS HEPARIN vs HERBALS\MITRAGYNINE HEPARIN vs HERBALS\PAULLINIA CUPANA SEED

Related Pages

HEPARIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression HEPARIN Demographics